Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 合肥立方制药股份有限公司（证券代码：003020）创建于2002年，是集药品制剂及原料药的研发、生产、销售于一体的创新型医药企业。公司于2020年12月15日在深交所主板成功挂牌上市，拥有6家医药工业企业和1家连锁药房，主要产品涉及心血管类用药、消化系统用药、中枢神经用药、眼科用药、皮肤外用药等领域。 公司已获得发明专利40余项，设有博士后工作站。公司先后承接各级政府多项重大科技项目，连续八年入选“中国化学制药工业企业综合实力百强”，并先后取得“国家火炬计划重点高新技术企业”、“安徽省创新型企业”、“省认定企业技术中心”、“中国医药工业最具投资价值企业”、“安徽省专精特新中小企业”、“安徽省药物缓控释工程技术研究中心”、“合肥市知识产权示范企业”等系列殊荣。 立方制药坚持“创新是企业最高效率”的理念，建立了由配方技术、制剂评价技术、制剂工程化技术以及关键设备技术四大部分组成的渗透泵控释技术平台，并不断提升渗透泵制剂产品开发与产业化能力。公司“难溶药物单层芯渗透泵控释技术研发与产业化应用”项目获得安徽省科学技术奖一等奖。立方制药在渗透泵控释技术产业化方面，实现了关键工艺、关键设备与关键辅料的集成创新。目前，公司已上市及在研渗透泵品种数量居国内领先。 公司不断加强企业技术创新体系建设，逐步建立完善中药、化学原料药、抗体药物研发与产业化平台。在中药与天然产物领域，建成了“破壁破膜环形逆流萃取与分离产业化技术平台”；在化学原料药领域，打造以高效、环保为核心的“绿色化学生产与研发技术平台”，为企业的产品开发提供了坚实的保障；全新打造的“抗体药物研发技术平台”，推动公司产品在高壁垒核药领域战略布局。 公司秉承“为人以诚、为事以专”的经营宗旨，积极倡导“按章办事，按程序办事”的企业文化，追求以效率为核心的制度化管理。 公司将发挥全体员工的智慧，务实创新，加快发展，用过硬的产品与服务，与供应商、分销商、医院和零售终端等合作伙伴精诚合作，同心缔造利益共同体，谱写立方制药更加灿烂辉煌的新篇章，为人类健康事业做出更大贡献。
Main Business 药品侧剂及原料药的研发、生产、销售，药品与医疗器械的批发、零售。
Legal Representative 季俊虬
Top Executives
董事长：季俊虬
副董事长：邓晓娟
董事：高美华,邓晓娟,崔欢喜,季铁城
独立董事：李进华,史静,潘立生
Top 5 Shareholder
Shareholder name Nature Holding Date
季俊虬限售股+流通A股27.24%30/06/2026
合肥立方投资集团有限公司流通A股19.71%30/06/2026
邓晓娟限售股+流通A股7.04%30/06/2026
邱世勋流通A股4.19%30/06/2026
高美华流通A股3.23%30/06/2026
Company Secretary 夏军
Solicitors 北京市竞天公诚律师事务所
Auditors 中汇会计师事务所（特殊普通合伙）
Tel No 0551-65350370
Fax No 0551-65350370
Website www.lifeon.cn
Email zqb@lifeon.cn
Company Address
Register: 安徽省合肥市长江西路669号立方厂区
Office: 安徽省合肥市长江西路669号立方厂区
Listing Date 15/12/2020
Shares Capital
Shares Capital: 228,218,618
Total A Share: 228,218,618
Listed A Share: 168,548,255
Non-tradable A Share: 59,670,363
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.870
DPS(RMB)* ¥ 0.500
NBV Per Share(RMB)* ¥ 9.512
Market Capitalization(RMB) 3.152B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.